Tag: Ofatumumab

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Ofatumumab

TG Therapeutics Touts Additional Positive Data, Plans Regulatory Submission for MS Drug

Added to Collection on: 2021-04-16 18:30:31

Tags for this article:

Drugs
Breakthrough therapy
Health sciences
Health care
Orphan drugs
Monoclonal antibodies
Multiple sclerosis
Ocrelizumab
Rituximab
Ofatumumab
CD20
Ibrutinib
ublituximab
TG THERAPEUTICS

Click the tags to see associated articles and topics

View Article Details
Brokers Issue Forecasts for Genmab A/S's FY2021 Earnings (NASDAQ:GMAB)

Added to Collection on: 2021-05-10 07:52:30

Tags for this article:

Drugs
Breakthrough therapy
Finance
Financial markets
Genmab
Monoclonal antibodies
BlackRock
Daratumumab
Stock
Securities research
Ofatumumab
Genmab A/S

Click the tags to see associated articles and topics

View Article Details
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology

Added to Collection on: 2021-07-29 13:18:45

Tags for this article:

Drugs
Health care
Health
Monoclonal antibodies
Breakthrough therapy
Ocrelizumab
Rituximab
CD20
Natalizumab
Multiple sclerosis
Ofatumumab
Draft:Teresa Frohman
Biogen Idec
Genzyme
Teva
Novartis
Ann Neurol
Celgene
Merck
Almirall
SANOFI-AVENTIS
sanofi-genzyme

Click the tags to see associated articles and topics

View Article Details
Genmab Stock: A Biotech Company On The Rise (NASDAQ:GMAB) | Seeking Alpha

Added to Collection on: 2022-03-12 21:01:30

Tags for this article:

Life Sciences
Health care
Health sciences
Biotechnology
Breakthrough therapy
Pharmaceutical industry
Genmab
Monoclonal antibodies
Seagen
Daratumumab
Tisotumab vedotin
Ofatumumab
Getty Images

Click the tags to see associated articles and topics

View Article Details
Ofatumumab Shows Long-term Safety and Efficacy, Does Not Restrict COVID-19 Vaccine ...

Added to Collection on: 2022-04-10 19:04:25

Tags for this article:

Life Sciences
Multiple sclerosis
Health sciences
Health care
Breakthrough therapy
Ofatumumab
Stephen L. Hauser
Novartis
American Academy of Neurology
Novartis Pharmaceuticals
Seattle

Click the tags to see associated articles and topics

View Article Details
Therapy Selection, DMT Switching Patterns in Patients With MS - Neurology Advisor

Added to Collection on: 2022-06-07 16:25:27

Tags for this article:

Drugs
Health sciences
Health care
Breakthrough therapy
Monoclonal antibodies
Ocrelizumab
Rituximab
CD20
Multiple sclerosis
N,N-Dimethyltryptamine
Ofatumumab
ICE

Click the tags to see associated articles and topics

View Article Details
Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of ...

Added to Collection on: 2022-07-02 14:12:22

Tags for this article:

Life Sciences
Health sciences
Health care
Breakthrough therapy
Immunosuppressants
Multiple sclerosis
Ofatumumab
Teriflunomide
Novartis
Heinz Wiendl
Multiple sclerosis drug pipeline

Click the tags to see associated articles and topics

View Article Details
Demand for Global Anti-CD20 Monoclonal Antibodies Market in 2022-2027 - Altcoinbeacon

Added to Collection on: 2022-11-29 07:59:37

Tags for this article:

Medical specialties
Life Sciences
Health
Immunology
Monoclonal antibodies
Genmab
CD20
Celltrion
Novartis
Immunomedics
Antibody
Ofatumumab

Click the tags to see associated articles and topics

View Article Details
'Wearing off' monoclonal antibodies leads to patient dissatisfaction, depression in MS

Added to Collection on: 2024-03-18 15:47:33

Tags for this article:

Monoclonal antibodies
Immunology
Orphan drugs
Immunosuppressants
Rituximab
Natalizumab
Email
Ocrelizumab
Multiple sclerosis
PHQ-9
Ofatumumab

Click the tags to see associated articles and topics

View Article Details
Ofatumumab Demonstrates Sustained Efficacy in Recently Diagnosed and Treatment-Naive ...

Added to Collection on: 2024-04-21 16:13:45

Tags for this article:

Immunosuppressants
Multiple sclerosis
Ofatumumab
CD20
Teriflunomide
Denver
Novartis
Oklahoma Medical Research Foundation

Click the tags to see associated articles and topics

View Article Details